Literature DB >> 21092926

Iatrogenic glaucoma secondary to medications.

M Reza Razeghinejad1, Jonathan S Myers, L Jay Katz.   

Abstract

Glaucoma is a progressive optic neuropathy with primary and secondary forms. Iatrogenic glaucoma secondary to medications is potentially blinding but preventable. Most drug profiles listing glaucoma as a contraindication or an adverse effect are concerned with inducing acute angle-closure glaucoma. Anticholinergic or adrenergic agents are the most common for inducing "pupillary block" angle-closure glaucoma. Patients with a narrow irido-corneal angle are at high risk. Sulfa drugs induce "non-pupillary block" angle-closure glaucoma as an idiosyncratic reaction to the drug in patients with an open or narrow irido-corneal angle. Steroids and a few antineoplastic agents induce open-angle glaucoma. The risk is higher with topical rather than systemic steroids. The first step in the management is discontinuation of the drug, followed by medical, laser, and, if necessary, surgical intervention. 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21092926     DOI: 10.1016/j.amjmed.2010.08.011

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  23 in total

Review 1.  Non-steroidal drug-induced glaucoma.

Authors:  M R Razeghinejad; M J Pro; L J Katz
Journal:  Eye (Lond)       Date:  2011-06-03       Impact factor: 3.775

2.  Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma.

Authors:  M Filippelli; R dell'Omo; A Gelso; M Rinaldi; S Bartollino; P Napolitano; A Russo; G Campagna; C Costagliola
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-08-18       Impact factor: 3.117

3.  Potentially inappropriate prescriptions of anticholinergic medications in patients with closed-angle glaucoma.

Authors:  Luis Fernando Valladales-Restrepo; Jorge Enrique Machado-Alba
Journal:  Int Ophthalmol       Date:  2019-12-03       Impact factor: 2.031

4.  Tissue and cellular characterisation of nucleolin in a murine model of corneal angiogenesis.

Authors:  Joaquín Quiroz-Mercado; Norma Ramírez-Velázquez; Graciela Partido; Edgar Zenteno; Raúl Chávez; Concepción Agundis-Mata; Maria Carmen Jiménez-Martínez; Yonathan Garfias
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-06-16       Impact factor: 3.117

Review 5.  Psychotropic Drug-Induced Glaucoma: A Practical Guide to Diagnosis and Management.

Authors:  Neeranjali S Jain; Claire W Ruan; Shanil R Dhanji; Richard J Symes
Journal:  CNS Drugs       Date:  2021-02-19       Impact factor: 5.749

Review 6.  Therapeutic Potential of Microvesicles in Cell Therapy and Regenerative Medicine of Ocular Diseases With an Especial Focus on Mesenchymal Stem Cells-Derived Microvesicles.

Authors:  Lina Moallemi Rad; Alexey V Yumashev; Bashdar Mahmud Hussen; Hazha Hadayat Jamad; Soudeh Ghafouri-Fard; Mohammad Taheri; Samaneh Rostami; Vahid Niazi; Mohammadreza Hajiesmaeili
Journal:  Front Genet       Date:  2022-03-29       Impact factor: 4.599

Review 7.  Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure.

Authors:  John D Sheppard; Timothy L Comstock; Megan E Cavet
Journal:  Adv Ther       Date:  2016-03-17       Impact factor: 3.845

8.  Abnormal increase of intraocular pressure in fellow eye after severe ocular trauma: A case report.

Authors:  Anu Vaajanen; Anja Tuulonen
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

Review 9.  A review of drug-induced acute angle closure glaucoma for non-ophthalmologists.

Authors:  Elliott Yann Ah-Kee; Eric Egong; Ahad Shafi; Lik Thai Lim; James Li Yim
Journal:  Qatar Med J       Date:  2015-05-10

10.  Bilateral acute closed angle glaucoma associated with the discontinuation of escitalopram: a case report.

Authors:  Sara AlQuorain; Sukayna Alfaraj; Mohammed Alshahrani
Journal:  Open Access Emerg Med       Date:  2016-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.